The U.S. drug maker Abbott Laboratories announced Tuesday that it will offer the AIDS-fighting drug Kaletra, also marketed under the name Aluvia, at a reduced price in Thailand and other low and lower-middle-income countries. The news would reportedly resolve a dispute between Thailand and Abbott over the high price of Kaletra.

Dr. Siriwat Tiptaradol, secretary-general of Thailand's Food and Drug Administration, was quoted saying in a news release from his agency, "The company today offered to lower its price for its AIDS drug Kaletra from 5,938 baht ($181) per patient per month to 3,488.20 baht ($107) per patient per month which could end up being cheaper than its generic version."

According to AP reports, officials from the health department would now consider Abbott's offer and the offer will now be forwarded by the FDA to the Public Health Ministry for further consideration.

Earlier this year, Thailand threatened to break the patent on Kaletra, if Abbott did not reduce prices. It also said that the country could provide cheaper generic versions of the drug to those in need, if it breaks the patent.

The Illinois-based company also added that it will offer its AIDS drugs to NGOs and governments of more than 40 low and low-middle income countries at a price of $1,000 per patient per year.